1. Manual small incision cataract surgery: a viable option for cataract with pseudoexfoliation
- Author
-
A R Rajalakshmi, Sruthi Rajendran, Krishnagopal Srikanth, and G Ezhumalai
- Subjects
medicine.medical_specialty ,genetic structures ,business.industry ,Pseudoexfoliation ,medicine.medical_treatment ,Pseudoexfoliation syndrome ,Cataract surgery ,medicine.disease ,Aphakia ,eye diseases ,Ophthalmology ,Cataracts ,Small incision ,Mydriasis ,medicine ,sense organs ,medicine.symptom ,business ,Zonular Dehiscence - Abstract
The aim of the study was to assess the spectrum of clinical presentation, intraoperative challenges and immediate surgical outcome of cataract patients with pseudoexfoliation syndrome (PXF) following manual small incision cataract surgery (MSICS). This prospective observational study which was conducted in a rural tertiary care hospital included adult patients with cataract and associated PXF. MSICS was performed for all after a complete ophthalmic and systemic examination. Clinical profile, intraoperative and post-operative complications were noted. Uncorrected visual acuity on first day post-surgery was used to assess the surgical outcome following MSICS. MSICS was performed in 80 eyes with varying grades of cataract and PXF. The mean age of the patients was 62.5 ± 8.9 years. PXF material on pupillary margin in 77(96%) patients was the most common finding noted. Majority of the patients had advanced cataract (72, 90%) and inadequate mydriasis (62, 77.5%). Posterior capsular rent (8, 10%) and zonular dehiscence (8, 10%) were the intraoperative difficulties faced. Uncorrected visual outcome on first post-operative day was moderate to good in 71 (88.8%) patients, limited by post-operative corneal oedema (21, 26.3%), iritis (31, 38.8%) and aphakia (9, 11.3%). Patients with pseudoexfoliation had poor pupillary dilatation, advanced cataracts and higher rate of posterior capsular rent. Our study showed good outcome of MSICS in PXF patients, even with advanced cataract suggesting that MSICS is a safe, effective and viable option for patients with PXF and cataract.
- Published
- 2021